The effect of Ecstasy on memory is moderated by a functional polymorphism in the cathechol-O-methyltransferase (COMT) gene

European Neuropsychopharmacology

Volumn 19, Issue 2, 2009, Pages 116-124

  Schilt, Thelma ^a,b   Koeter, Maarten W J ^a,b   de Win, Maartje M L ^b   Zinkstok, Janneke R ^b   van Amelsvoort, Thérèse A ^b   Schmand, Ben ^b   den Brink, Wim van ^a,b  

^a AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

3,4 methylenedioxymethamphetamine; Catechol O methyltransferase; MDMA; Memory; Neuropsychology

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CATECHOL METHYLTRANSFERASE; METHIONINE; VALINE;

ADULT; ARTICLE; COMT GENE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG METABOLISM; FEMALE; GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN FUNCTION; VERBAL MEMORY;

ADOLESCENT; ADULT; CATECHOL O-METHYLTRANSFERASE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INTELLIGENCE TESTS; MALE; MEMORY; MENTAL RECALL; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; SEROTONIN AGENTS; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS; VERBAL LEARNING; YOUNG ADULT;

EID: 57749207924     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.10.004     Document Type: Article

References (57)

1. Back-Madruga C., Boone K.B., Chang L., Grob C.S., Lee A., Nations H., and Poland R.E. Neuropsychological effects of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in recreational users. Clin. Neuropsychol. 17 (2003) 446-459
2. Bor D., Cumming N., Scott C.E., and Owen A.M. Prefrontal cortical involvement in verbal encoding strategies. Eur. J. Neurosci. 19 (2004) 3365-3370
3. Brodkin J., Malyala A., and Nash J.F. Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol. Biochem. Behav. 45 (1993) 647-653
4. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., Kolachana B.S., Hyde T.M., Herman M.M., Apud J., Egan M.F., Kleinman J.E., and Weinberger D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 75 (2004) 807-821
5. Colado M.I., O'Shea E., and Green A.R. Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berl) 173 (2004) 249-263
6. Dafters R.I., Duffy F., O'Donnell P.J., and Bouquet C. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence. Psychopharmacology (Berl) 145 (1999) 82-90
7. de Win M.M., Jager G., Vervaeke H.K., Schilt T., Reneman L., Booij J., Verhulst F.C., den Heeten G.J., Ramsey N.F., Korf D.J., and van den Brink W. The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance. Int. J. Methods Psychiatr. Res. 14 (2005) 167-185
8. Drugs Informatie en Monitoring Systeem. Jaarbericht 2003. Utrecht: DIMS/Trimbos-instituut (2003)
9. Drugs Informatie en Monitoring Systeem. Jaarbericht 2004. Utrecht: DIMS/Trimbos-instituut (2004)
10. Fleiss J.L. The Design and Analysis of Clinical Experiments (1986), John Wiley and Sons, New York
11. Fox H.C., Parrott A.C., and Turner J.J. Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J. Psychopharmacol. 15 (2001) 273-281
12. Gouzoulis-Mayfrank E., and Daumann J. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?. Addiction 101 (2006) 348-361
13. Gouzoulis-Mayfrank E., Thimm B., Rezk M., Hensen G., and Daumann J. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuropsychopharmacol Biol. Psychiatry 27 (2003) 819-827
14. Gouzoulis-Mayfrank E., Fischermann T., Rezk M., Thimm B., Hensen G., and Daumann J. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use. Drug Alcohol Depend. 78 (2005) 317-323
15. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55 (2003) 463-508
16. Green A.R., Sanchez V., O'Shea E., Saadat K.S., Elliott J.M., and Colado M.I. Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ("binge" ingestion) low dose of MDMA. Psychopharmacology (Berl) 173 (2004) 264-269
17. Gudelsky G.A., and Nash J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem. 66 (1996) 243-249
18. Heydari A., Yeo K.R., Lennard M.S., Ellis S.W., Tucker G.T., and Rostami-Hodjegan A. The mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine (MDMA). Drug Metab. Dispos. 32 (2004) 1213-1217
19. Jones D.C., Lau S.S., and Monks T.J. Thioether metabolites of MDA and MDMA inhibit hSERT function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells. J. Pharmacol. Exp. Ther. 311 (2004) 298-306
20. Kanthasamy A., Sprague J.E., Shotwell J.R., and Nichols D.E. Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum. Neuroscience 114 (2002) 917-924
21. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., and Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6 (1996) 243-250
22. Matsumoto M., Weickert C.S., Akil M., Lipska B.K., Hyde T.M., Herman M.M., Kleinman J.E., and Weinberger D.R. Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience 116 (2004) 127-137
23. Mattay V.S., Goldberg T.E., Fera F., Hariri A.R., Tessitore A., Egan M.F., Kolachana B., Callicott J.H., and Weinberger D.R. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Acad. Sci. U S A 100 (2003) 6186-6191
24. McCardle K., Luebbers S., Carter J.D., Croft R.J., and Stough C. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology (Berl) 173 (2004) 434-439
25. Mechan A.O., Esteban B., O'Shea E., Elliott J.M., Colado M.I., and Green A.R. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br. J. Pharmacol. 135 (2002) 170-180
26. Meneses A. 5-HT system and cognition. Neuroscience and Biobehavioral Reviews 23 (1999) 1111-1125
27. Nabben T., Benschop A., and Korf D.J. Antenne 2004 Trends in alcohol, tabak en drugs bij jonge Amsterdammers. Antenne (2005), Rozenberg Publishers, Amsterdam
28. Nash J.F., and Brodkin J. Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J. Pharmacol. Exp. Ther. 259 (1991) 820-825
29. Nelson H.E., and O'Connell A. Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex 14 (1978) 234-244
30. Palmatier M.A., Kang A.M., and Kidd K.K. Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol. Psychiatry 46 (1999) 557-567
31. Parrott A.C. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum. Psychopharmacol. 16 (2001) 557-577
32. Pirker W., Asenbaum S., Hauk M., Kandlhofer S., Tauscher J., Willeit M., Neumeister A., Praschak-Rieder N., Angelberger P., and Brucke T. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J. Nucl. Med. 41 (2000) 36-44
33. Quednow B.B., Jessen F., Kuhn K.U., Maier W., Daum I., and Wagner M. Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction. J. Psychopharmacol. 20 (2006) 373-384
34. Ramamoorthy Y., Yu A.M., Suh N., Haining R.L., Tyndale R.F., and Sellers E.M. Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem. Pharmacol. 63 (2002) 2111-2119
35. Reneman L., Majoie C.B., Schmand B., van den Brink W., and den Heeten G.J. Prefrontal N-acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: preliminary report. Biol. Psychiatry 50 (2001) 550-554
36. Reneman L., de Win M.M., van den Brink W., Booij J., and den Heeten G.J. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J. Psychopharmacol. 20 (2006) 164-175
37. Reneman L., Schilt T., de Win M.M., Booij J., Schmand B., van den Brink W., and Bakker O. Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users. J. Psychopharmacol. 20 (2006) 389-399
38. Rey A. L'examen clinique en psychologie (1964), Presses Universitaires de France, Paris
39. Ricaurte G.A., Yuan J., and McCann U.D. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42 (2000) 5-10
40. Roiser J.P., Cook L.J., Cooper J.D., Rubinsztein D.C., and Sahakian B.J. Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users. Am. J. Psychiatry 162 (2005) 609-612
41. Roiser J.P., Rogers R.D., Cook L.J., and Sahakian B.J. The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls. Psychopharmacology (Berl) 188 (2006) 213-227
42. Sauer S., and Gut I.G. Genotyping single-nucleotide polymorphisms by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 782 (2002) 73-87
43. Savage C.R., Deckersbach T., Heckers S., Wagner A.D., Schacter D.L., Alpert N.M., Fischman A.J., and Rauch S.L. Prefrontal regions supporting spontaneous and directed application of verbal learning strategies: evidence from PET. Brain 124 (2001) 219-231
44. Schilt T., de Win M.M., Koeter M., Jager G., Korf D.J., van den Brink W., and Schmand B. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Arch. Gen. Psychiatry 64 (2007) 728-736
45. Schmand B., Bakker D., Saan R., and Louman J. [The Dutch Reading Test for Adults: a measure of premorbid intelligence level]. Tijdschr. Gerontol. Geriatr. 22 (1991) 15-19
46. Shankaran M., Yamamoto B.K., and Gudelsky G.A. Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum. J. Neurochem. 72 (1999) 2516-2522
47. Sprague J.E., and Nichols D.E. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther. 273 (1995) 667-673
48. Sprague J.E., Everman S.L., and Nichols D.E. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 19 (1998) 427-441
49. Topp L., Barker B., and Degenhardt L. The external validity of results derived from ecstasy users recruited using purposive sampling strategies. Drug Alcohol Depend. 73 (2004) 33-40
50. Tucker G.T., Lennard M.S., Ellis S.W., Woods H.F., Cho A.K., Lin L.Y., Hiratsuka A., Schmitz D.A., and Chu T.Y. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem. Pharmacol. 47 (1994) 1151-1156
51. Tunbridge E.M., Harrison P.J., and Weinberger D.R. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol. Psychiatry 60 (2006) 141-151
52. Van de Wijngaart G., Braam R., de Bruin D., Fris M., Maalsté N., and Verbraeck H. Ecstasy in het uitgaanscircuit (Ecstasy and the Dutch rave scene: A socio-epidemiologic study on the nature and extent of, and the risks involved in using ecstasy and other party drugs at dance events). 1997 (1997), Addiction Research Institute, Utrecht
53. Van der Elst W., Van Boxtel M.P., Van Breukelen G.J., and Jolles J. Rey's verbal learning test: normative data for 1855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. J. Int. Neuropsychol. Soc. 11 (2005) 290-302
54. Vervaeke H.K., Korf D.J., Benschop A., and van den Brink W. How to find future ecstasy-users: targeted and snowball sampling in an ethically sensitive context. Addict Behav. 32 (2006) 1705-1713
55. Weinshilboum R.M., Otterness D.M., and Szumlanski C.L. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 19-52
56. White S.R., Obradovic T., Imel K.M., and Wheaton M.J. The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. Prog. Neurobiol. 49 (1996) 455-479
57. Zinkstok J., Schmitz N., Van Amelsvoort T., De Win M., Van den Brink W., Baas F., and Linszen D. The COMT val158met polymorphism and brain morphometry in healthy young adults. Neurosci. Lett. 405 (2006) 34-39